GCT1184 03 / RAINFOL 03 / GOG 3128 / ENGOT en31 A global, phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice of chemotherapy in patients with endometrial cancer after platinum-based chemotherapy and programmed death-ligand 1 inhibition